Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Topline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma expected to be released in December 2024 OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a...
OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief...
OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to...
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.13 | 60.4278074866 | 1.87 | 4.77 | 1.8248 | 130364 | 3.70259323 | CS |
| 4 | 0.63 | 26.582278481 | 2.37 | 4.77 | 1.58 | 56377 | 3.0135425 | CS |
| 12 | -0.5 | -14.2857142857 | 3.5 | 4.77 | 1.58 | 39769 | 2.97799549 | CS |
| 26 | -1 | -25 | 4 | 4.9 | 1.58 | 122391 | 3.656465 | CS |
| 52 | -1 | -25 | 4 | 4.9 | 1.58 | 122391 | 3.656465 | CS |
| 156 | -1 | -25 | 4 | 4.9 | 1.58 | 122391 | 3.656465 | CS |
| 260 | -1 | -25 | 4 | 4.9 | 1.58 | 122391 | 3.656465 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| MSTZT Rex 2X Inverse MSTR Daily Target ETF | US$ 0,841198 (-7,56%) | 946,17M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 30,70 (7,87%) | 102,19M |
| NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 3,535 (4,59%) | 65,43M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5,835 (0,43%) | 52,08M |
| SENSSenseonics Holdings Inc | US$ 0,46 (6,70%) | 51,08M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
